Glucosylceramide: A marker for multiple-drug resistant cancers

Anticancer Research

Volumn 18, Issue 1 B, 1998, Pages 475-480

  Lucci, Anthony ^a   Cho, Won I ^a   Han, Tie Yan ^a   Giuliano, Armando E ^a   Morton, Donald L ^a   Cabot, Myles C ^a  

^a JOHN WAYNE CANCER INSTITUTE   (United States)

Author keywords

Glucosylceramide; Melanoma; Multiple drug resistance; Tumor marker

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; GLUCOSYLCERAMIDE; LIPID; PALMITIC ACID; TAMOXIFEN; TRITIUM; TUMOR MARKER; VINBLASTINE;

ADOLESCENT; ADULT; ARTICLE; BREAST TUMOR; CANCER CHEMOTHERAPY; CELL CULTURE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG SENSITIVITY; FEMALE; HUMAN; HUMAN CELL; ISOTOPE LABELING; LIPID ANALYSIS; MALE; MELANOMA; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; THIN LAYER CHROMATOGRAPHY;

ADOLESCENT; ADULT; BREAST NEOPLASMS; DRUG RESISTANCE, MULTIPLE; FEMALE; GLUCOSYLCERAMIDES; HUMANS; MALE; MELANOMA; MIDDLE AGED; NEOPLASMS; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 0031899553     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Gottesman MM: How cancer cells evade chemotherapy: Sixteenth Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res 55: 747-754, 1993.
2. Juliano RL and Ling V: A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 455: 152-162, 1976.
3. Bradley G, Juranka PF and Ling V: Mechanism of multidrug resistance. Biochim Biophys Acta 948: 87-128, 1988.
4. Lavie Y, Cao H-t, Bursten SL, Giuliano AE and Cabot MC: Accumulation of glucosylceramides in multidrug-resistant cancer cells. J Biol Chem 277: 19530-19536, 1996.
5. Glew RH: Pathways of metabolism of special lipids. In: Textbook of biochemistry with clinical correlations (Devlin TM, ed). New York, Wiley-Liss Publishers, 1992, pp 453-460.
6. Marsh NL, Elias PM and Holleran WM: Glucosylceramides stimulate murine epidermal hyperproliferation. J Clin Invest 95: 2903-2909, 1995.
7. Miller SP, Zirzow GC, Doppelt SH, Brady RO and Barton NW: Analysis of the lipids of normal and Gaucher bone marrow. J Lab Clin Med 127: 353-358, 1996.
8. Bligh EG and Dyer WJ: A rapid method of total lipid extraction and purification. Can J Biochem Physiol 37: 911-917, 1959.
9. Skipper HE and Schabel FM Jr: Tumor stem cell heterogeneity: Implications with respect to classification of cancers by chemotherapeutic effect. Cancer Treat Rep 68: 43-61, 1984.
10. Selby P, Buick RN and Tannock I: A critical appraisal of the "human tumor stem-cell assay". N Engl J Med 308: 129-134, 1983.
11. Graham CH, Kobayashi H, Stankiewicz KS, Man S, Kapitain SJ and Kerbel RS: Rapid acquisition of multicellular drug resistance after a single exposure of mammary tumor cells to antitumor alkylating agents. J Natl Cancer Inst 86: 975-982, 1994.
12. Johnston SRD, Haynes BP, Smith IE, Jarman M, Sacks NPM, Ebbs SR and Dowsett M: Acquired tamoxifen resistance in human breast cancer and reduced intra-tumoral drug concentration. Lancet 342: 1521-1522, 1993.
13. Oka M, Fukuda M, Narasaki F, Nakano R, Ikeda K, Takatani H, Fukuda M, Fujino S, Kohno S and Soda H: Multidrug resistance-associated protein (MRP) confers drug resistance in lung cancer [abstract]. Proc Am Soc Clin Oncol 15: 187, 1996.
14. Schroder CP, Godwin AK, O'Dwyer PJ, Tew KD, Hamilton TC and Ozols RF: Glutathione and drug resistance. Cancer Invest 14: 158-168, 1996.
15. Volm M, Kastel M, Mattern J and Efferth T: Expression of resistance factors (P-glycoprotein, glutathione S-transferase-π and topoisomerase II) and their interrelationship to proto-oncogene products in renal cell carcinomas. Cancer 71: 3981-3987, 1993.
16. Hayashi K, Danenberg KD, Metzger R, Solonga D, Lenz H-J, Leichman CG, Danenberg PV and Leichman L: Differential thymidylate synthase (ts) gene expression in squamous cell carcinoma and adenocarcinoma of the esophagus [abstract]. Proc Am Soc Clin Oncol 15: 214, 1996.
17. Marsoni S, Hoth D, Simon R, Leyland-Jones B, De Rosa M and Wittes RE: Clinical drug development: an analysis of phase II trials, 1970-1985. Cancer Treat Rep 71: 71-80, 1987.
18. Gulbins E, Bissonnette R, Mahboubi A, Martin S, Nishioka W, Brunner T, Baier G, Baier-Bitterlich G, Byrd C, Lang F, Kolesnick R, Altman A and Green D: Fas-induced apoptosis is mediated via a ceramide-initiated RAS signaling pathway. Immunity 2: 341-351, 1995.
19. Haimovjtz-Friedman A, Kan CC, Ehleiter D, Persaud RS, McLoughlin M, Fuks Z and Kolesnick RN: Ionizing radiation acts on cellular membranes to generate ceramide and initiate apoptosis. J Exp Med 180: 525-535, 1994.
20. Bose R, Verheij M, Haimovitz-Friedman A, Scotto K, Fuks Z and Kolesnick R: Ceramide synthase mediates daunorubicin-induced apoptosis: an alternative mechanism for generating death signals. Cell 82: 405-414, 1995.
21. Kirk J, Houlbrook S, Stuart NSA, Stratford LI, Harris AL and Carmichael J: Differential modulation of doxorubicin toxicity to multidrug and intrinsically drug resistant cell lines by anti-oestrogens and their major metabolites. Br J Cancer 67: 1189-1195, 1993.
22. Dalton WS, Grogan TM, Meltzer PS, Scheper RJ, Durie BG, Taylor CW, Miller TP and Salmon SE: Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of p-grycoprotein and potential circumvention by addition of verapamil to chemotherapy. J Clin Oncol 7: 415-424, 1989.
23. Rischin D, Webster LK, Millward MJ, Linahan BM, Toner GC, Woollett AM, Morton CG and Bishop JF: Cremophor pharmacokinetics in patients receiving 3-, 6-, and 24-hour infusions of paclitaxel. J Natl Cancer Inst 88: 1297-1301, 1996.
24. Watanabe T, Tsuge H, Oh-Hara T, Naito M and Tsuruo T: Comparative study on reversal efficacy of SDZ PSC 833, cyclosporin A and verapamil on multidrug resistance in vitro and in vivo. Acta Oncol 34: 235-241, 1995.
25. Archinal-Mattheis A, Rzepka RW, Watanabe T, Kokubu N, Itoh Y, Combates NJ, Bair KW and Cohen D: Analysis of the interactions of SDZ PSC 833 ([3'-keto-Bmt1)-Val2]-Cyclosporine), a multidrug resistance modulator, with P-glycoprotein. Oncol Res 7: 603-610, 1995.
26. Boesch D, Muller K, Pourtier-Manzanedo A and Loor F: Restoration of daunomycin retention in multidrug-resistant P388 cells by submicromolar concentrations of SDZ PSC 833, a nonimmunosuppressive cyclosporin derivative. Exp Cell Res 196: 26-32, 1991.
27. Lavie Y, Cao Ht, Volner A, Lucci A, Man TY, Geffen V, Giuliano AE and Cabot MC: Agents that reverse multidrug resistance, tamoxifen, verapamil, and cyclosporin A, block glycosphingolipid metabolism by inhibiting ceramide glycosylation in human cancer cells. J Biol Chem 272: 1682-1687, 1997.
28. Cabot MC, Giuliano AE, Volner A and Man T-Y: Tamoxifen retards grycosphingolipid metabolism in human cancer cells. FEBS Lett 394: 129-131, 1996.
29. List AF, Spier C, Greer J, Azar C, Hutter J, Wolff S, Salmon S, Futscher B and Dalton W: Biochemical modulation of anthracycline resistance (MDR) in acute leukemia with cyclosporin-A (CSA) [abstract]. Proc Am Soc Clin Oncol 11: 264, 1992.
30. Ohtsu T, Tanigawara Y, Fujii H, Wakita H, Igarashi T, Itoh K, Morikawa H and Saoaki Y: A phase I trial of intravenous SDZ PSC 833 (PSC) in combination with doxorubicin (DOX) as a modulator of multidrug resistance (MDR) in cancer patients [abstract]. Proc Am Soc Clin Oncol 15: 487, 1996.
31. Lehnert M, Mross K, Schuller J, Thurlimann B, Kroger N and Kupper H: Dexverapamil is able to overcome epirubicin resistance in metastatic breast cancer [abstract], Proc Am Soc Clin Oncol 15: 187, 1996.
32. Bates SE, Wilson WH, Fojo AT, Alvarez M, Zhan Z, Regis J, Robey R, Hose C, Monks A, Kang YK and Chabner B: Clinical reversal of multidrug resistance. Stem Cells 14: 56-63, 1996.